Breakout Ventures’ Post

The journey of bringing bio-based technologies from the lab to the market is anything but easy, and having a trusted guide can make all the difference.  𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐚𝐝𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐟𝐢𝐯𝐞 𝐧𝐞𝐰 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦! These industry experts will support Breakout, our portfolio, and our broader ecosystem — from diligencing investment opportunities to commercializing new tech. 𝐏𝐥𝐞𝐚𝐬𝐞 𝐣𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐰𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠: ✨ Sridhar Iyengar, PhD: Founder and Chief Strategy Officer of Elemental Machines ✨ Coco Krumme, PhD: Founder of Leeward Co ✨ Rebecca Nugent, PhD: VP of HTP Operations at Tessera Therapeutics ✨ Walter Solomon: Board Director and Advisor ✨ Ilan Zipkin, PhD: Founder and CEO of Supercede Therapeutics, Inc. Breakout Ventures is built on the theory that creative bioscience founders need more than just capital to take on the world's biggest challenges in human health and sustainability. Thank you to our venture partners, advisors, and community members for helping us build a bio-based future! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/gp4SADTe

Congratulations to the Cytovale team on receiving the San Francisco Business Times Inno Award in Healthcare! 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🏆 The Inno Awards honor Bay Area startups that are leading their fields in AI chips, medical devices and clothing manufacturing. 🔬 Cytovale was recognized as a winner in the Healthcare division for building an FDA-approved diagnostic machine that can diagnose sepsis in as little as 10 minutes 🏥 With sepsis being a leading cause of death in U.S. hospitals that costs our healthcare system $Billions each year, this breakthrough technology is already helping doctors save countless patients' lives. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/g-Nm3nfe

One week until the Nucleate panel on building careers in biotech startups and venture capital, and we've already got over 500 attendees signed up to join! Moderated by Breakout Ventures' Director of Community, Susanna Harris, PhD, this panel of bio+tech investors and talent partners will explain how to join the world of early-stage biotech venture and entrepreneurship.   The 1-hour virtual panel features: • Eric Dai - Investor, Dimension • Natalie Estrella - Talent Partner, Cantos • Rahil Haneef - Principal & Senior VP, LifeSci Search & LifeSci Partners • Yusuf Uddin, PhD - Head of Talent, KdT Ventures Register for the live event on August 1st at 3pm ET: https://lu.ma/y795l12s #BiotechVenture #BiotechVC #AltAc #BioCareers #VCCareers

“When you’ve built this really automated lab, you actually have the ability to do things that you couldn’t really do before.” ~ Ari Gesher, on why Parallel Bio is building a “lights-off” lab for drug discovery. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 💻 Newly appointed as the Head of Technology at Parallel Bio, Ari Gesher, is applying his experience at SourceForge and Palantir Technologies to automate drug development and testing. 🔬 The fully-automated "lights-off" lab allows biologists to focus on designing experiments rather than executing them, automating tasks to increase the speed and scope of scientific inquiry. 🚀 Reflecting on historical tech transformations and the potential of integrating computing and automation in research, Gesher predicts the revolution in scientific discovery is just beginning. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐰𝐢𝐭𝐡 Brian K. Buntz 𝐢𝐧 R&D - Research & Development World: https://lnkd.in/dkiahtzz

RNA-based therapies treat a wide range of diseases—from genetic disorders to infections to cancers. Breakthrough tech from EnPlusOne Biosciences could make treatments cheaper, better, and more accessible. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🔬 EnPlusOne Biosciences' new enzymatic RNA synthesis process allows for a wider range of RNA chemistries, enhancing the potential for diverse RNA-based therapies. 🌿 Originating from the Wyss Institute at Harvard University, the ezRNA™ platform uses water and enzymes to produce RNA, eliminating toxic byproducts and ensuring sustainability. 📈 As published in Nature Biotechnology, the new process achieves 95% efficiency and supports rapid scale-up to address the increasing global demand for RNA therapeutics. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲: https://lnkd.in/dnkHTWf9

Each year, a 𝘲𝘶𝘢𝘳𝘵𝘦𝘳 𝘰𝘧 𝘢 𝘮𝘪𝘭𝘭𝘪𝘰𝘯 patients die of sepsis at US hospitals. What if 1-in-5 of those people could be saved with just a simple blood draw? 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🏥 Sepsis is one of the most deadly and most expensive conditions in US hospitals, with over 1.7 million people affected annually. 🖥 Cytovale's Intellisep AI-driven diagnostic tool accurately predicts the risk of sepsis in minutes so clinicians can stop the condition before it turns deadly. 💕 Our Lady of the Lake reported that the tool has reduced sepsis-related mortality by 20%, while saving an average of $1,400 in care costs per patient. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲: https://lnkd.in/emksAJqK

Over 𝘵𝘸𝘰 𝘮𝘪𝘭𝘭𝘪𝘰𝘯 𝘵𝘰𝘯𝘴 of denim jeans end up in landfills each year. That's a whole lot of material ready to become... building blocks? To turn wasted denim into sustainable architectural materials, Artistic Garment Industries (AGI Denim) is partnering with Breakout Ventures' portfolio company Ecovative - the mycelium technology company. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🌿 Ecovative's mycelium technology harnesses the root-like fiber of fungi to create biodegradable materials for industries from fashion to structural design. 👖 Mixing discarded jeans with the microbe's feedstock produces mycelium bricks in various denim shades, creating building blocks that are pleasing to the eye 𝘢𝘯𝘥 the environment. 🌎 AGI will present the mycelium bricks at Kingpins New York to encourage the fashion world to reimagine of denim's possibilities. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐬𝐭𝐨𝐫𝐲: https://lnkd.in/e-tuGW7F

The $135 billion global hygiene industry has a 𝘣𝘪𝘨 sustainability problem - one that ZymoChem is solving with biology. Introducing BAYSE™, the world's first scalable, 100% bio-based, and biodegradable Super Absorbent Polymer 𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🌱 Powered with biology, BAYSE™ is made from renewable resources, maintains a lower carbon footprint, and is uniquely biodegradable. 💡 Replacing traditional, fossil fuel-based Super Absorbent Polymers (SAPs) with bio-based SAPs would drastically reduce the environmental impact of countless consumer products, from diapers to cosmetics. 💸 Thanks to ZymoChem's proprietary biomanufacturing platform, the production of BAYSE™ is cost-competitive with that of traditional SAPs, ensuring sustainability without added expense. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐧𝐞𝐰𝐬: https://lnkd.in/enCnExBU